Methods of treating neoplastic, autoimmune and inflammatory diseases

Abstract

Methods of treating cancer and autoimmune and inflammatory diseases are provided.

1 . A method of treating a patient having acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), comprising administering an unconjugated humanized M195 antibody to the patient at a dose of 1.5 to about 12 mg/kg body weight, whereby progression of the AML or MDS is inhibited. 
     
     
         2 . The method of  claim 1 , wherein the antibody is administered at weekly intervals for a period of about one to three months. 
     
     
         3 . The method of  claim 2 , further comprising administering the antibody at biweekly intervals for a period of one to six months. 
     
     
         4 - 10 . (canceled) 
     
     
         11 . The method of  claim 1 , whereby at least one symptom of AML associated cachexia is reduced. 
     
     
         12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the humanized M195 antibody decreases the number of involved non-malignant effector cells, and/or decreases the levels of one or more inflammatory cytokines, chemokines or growth factors, in the patient. 
     
     
         14 - 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the patient is at least 60 years of age. 
     
     
         19 - 27 . (canceled) 
     
     
         28 . A method of treating acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in a patient, or of preventing or delaying recurrence of AML or MDS in a patient in remission, comprising administering an unconjugated humanized M195 antibody to the patient at a dose of 550-650 mg regardless of body weight. 
     
     
         29 . The method of  claim 28 , wherein the antibody is administered at weekly intervals for a period of about one to three months. 
     
     
         30 . The method of  claim 28 , whereby at least one symptom of AML associated cachexia is reduced. 
     
     
         31 . The method of  claim 28 , wherein the patient is at least 60 years of age. 
     
     
         32 . The method of  claim 28 , wherein the antibody is administered at a dose of about 600 mg. 
     
     
         33 . The method of  claim 32 , wherein the antibody is administered at weekly intervals for a period of about one to three months. 
     
     
         34 . The method of  claim 32 , wherein the patient is at least 60 years of age.